4 completed, 3 recruiting, 1 active not recruiting, 1 not yet recruiting. 10 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 4, Recruiting 3, Active not recruiting 1, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 5 | Recruiting 2, Active not recruiting 1, Completed 1, Not yet recruiting 1 |
Follow Duchenne Muscular Dystrophy (DMD): new trials by email Literature Review of Duchenne Muscular Dystrophy (DMD) trials Research Report on Duchenne Muscular Dystrophy (DMD)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy Semaglutide (Rybelsus®), Placebo - Duchenne Muscular Dystrophy (DMD) | Phase 1 / Phase 2 | Not yet recruiting | Vanderbilt University Medical Center | 30 | 2026-09-01 | 2026-06-11 |
| Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy SGLT-2 inhibitor, SGLT2 inhibitor - Duchenne Muscular Dystrophy (DMD) | Phase 1 | Recruiting | Vanderbilt University Medical Center | 10 | 2026-07-01 | 2026-08-24 |
| A Trial to Investigate the Safety and Pharmacokinetics of GRT6019 in Healthy Male Participants GRT6019 - Duchenne Muscular Dystrophy (DMD) | Phase 1 | Completed | Grünenthal GmbH | 24 | 2026-01-06 | 2026-08-12 |
| A Trial to Investigate Safety and Pharmacokinetics of GRT6019, Including Food Effect, in Healthy Male Participants GRT6019 - Duchenne Muscular Dystrophy (DMD) | Phase 1 | Completed | Grünenthal GmbH | 18 | 2025-11-21 | 2026-02-13 |
| A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45 ENTR-601-45, ENTR-601-45 - matching placebo - Duchenne Muscular Dystrophy (DMD) | Phase 1 / Phase 2 | Recruiting | Entrada Therapeutics, Inc. | 24 | 2025-08-30 | 2026-08-13 |
| A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44 ENTR-601-44, ENTR-601-44 - matching placebo - Duchenne Muscular Dystrophy (DMD) | Phase 1 / Phase 2 | Recruiting | Entrada Therapeutics, Inc. | 24 | 2025-06-30 | 2026-08-13 |
| Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping DYNE-251, Placebo - Duchenne Muscular Dystrophy (DMD) | Phase 1 / Phase 2 | Active not recruiting | Dyne Therapeutics | 86 | 2022-08-12 | 2026-08-11 |
| A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD) Bocidelpar, Placebo - Duchenne Muscular Dystrophy (DMD) | Phase 1 | Terminated | Astellas Pharma Inc | 8 | 2021-02-24 | 2024-10-22 |
| A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children With DMD Givinostat - Duchenne Muscular Dystrophy (DMD) | Phase 1 / Phase 2 | Completed | Italfarmaco | 20 | 2013-04-01 | 2023-11-07 |
| To Compare the Pharmacokinetics Profiles of ISO 20, IBU 200 and IBU Plus ISO Combinations 200 + 20 Isosorbide Dinitrate, Ibuprofen, Ibuprofen and Isosorbide Dinitrate combination - Duchenne Muscular Dystrophy (DMD) | Phase 1 | Completed | Parent Project, Italy | 12 | 2011-10-01 | 2018-08-31 |
Muscular Dystrophy, Duchenne (10) · Muscular Dystrophies (2) · Cardiomyopathies (1) · Heart Failure (1) · Obesity (1) · Rare Diseases (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10) · Genetic Diseases, Inborn (10) · Genetic Diseases, X-Linked (10) · Muscular Diseases (10) · Muscular Disorders, Atrophic (10) · Musculoskeletal Diseases (10) · Nervous System Diseases (10) · Neuromuscular Diseases (10) · Muscular Dystrophies (8) · Pathological Conditions, Signs and Symptoms (2) · Body Weight (1) · Cardiovascular Diseases (1) · Disease Attributes (1) · Heart Diseases (1) · Nutrition Disorders (1)
Drug Evaluation (1) · Ibuprofen (1) · Isosorbide Dinitrate (1) · Sodium-Glucose Transporter 2 Inhibitors (1) · givinostat (1) · givinostat hydrochloride (1) · semaglutide (1)
Entrada Therapeutics, Inc. (2) · Grünenthal GmbH (2) · Vanderbilt University Medical Center (2) · Astellas Pharma Inc (1) · Dyne Therapeutics (1) · Italfarmaco (1) · Parent Project, Italy (1)
Italy (5) · United States (5) · Belgium (3) · Spain (3) · United Kingdom (3) · Australia (1) · Canada (1) · France (1) · Ireland (1) · Netherlands (1) · South Korea (1)
Emilio Clementi (1) · Enrico Bertini, MD (1) · Larry W. Markham, MD (1)
2023 (1), R61HL180327 (1)